Last reviewed · How we verify

Tacrolimus &entecavir — Competitive Intelligence Brief

Tacrolimus &entecavir (Tacrolimus &entecavir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination immunosuppressant and antiviral. Area: Immunology / Virology.

marketed Combination immunosuppressant and antiviral Calcineurin (tacrolimus); Hepatitis B virus reverse transcriptase (entecavir) Immunology / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Tacrolimus &entecavir (Tacrolimus &entecavir) — Guangdong Provincial People's Hospital. This combination uses tacrolimus to suppress immune rejection and entecavir to inhibit hepatitis B virus reverse transcriptase.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tacrolimus &entecavir TARGET Tacrolimus &entecavir Guangdong Provincial People's Hospital marketed Combination immunosuppressant and antiviral Calcineurin (tacrolimus); Hepatitis B virus reverse transcriptase (entecavir)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination immunosuppressant and antiviral class)

  1. Guangdong Provincial People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tacrolimus &entecavir — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-entecavir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: